This clinical trial focuses on treating patients with Stage IV Squamous Non-Small Cell Lung Cancer who have previously received other treatments. The study will test three different medications: Raludotatug Deruxtecan (also known as MK-5909), Ifinatamab Deruxtecan (also known as MK-2400), and Docetaxel. These medications are given through intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The main purpose of this study is to determine how well these treatments work in fighting lung cancer and to evaluate their safety when used individually. The medications will be administered over a period of up to 24 months, with different dosing schedules for each drug. Raludotatug Deruxtecan will be given at doses up to 5.6 mg per kilogram of body weight, Ifinatamab Deruxtecan at doses up to 12 mg per kilogram, and Docetaxel at doses up to 75 mg per square meter of body surface area.

During the study, doctors will monitor how the cancer responds to treatment and track any side effects that may occur. The study will measure how many patients’ tumors shrink or disappear, how long the treatment effects last, how long patients live without their cancer getting worse, and overall survival time. This research is part of a larger study called KEYMAKER-U01, which is investigating various treatment options for lung cancer.